GLUCOSE 5 % INTRAVENOUS INFUSION BP Israel - English - Ministry of Health

glucose 5 % intravenous infusion bp

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Compound Sodium Lactate Intravenous Infusion BP (Hartmann's Solution) Malta - English - Medicines Authority

compound sodium lactate intravenous infusion bp (hartmann's solution)

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - calcium chloride, dihydrate, potassium chloride, sodium chloride, sodium lactate - solution for infusion - sodium chloride 6 g/l sodium lactate 3.12 g/l calcium chloride dihydrate 0.27 g/l potassium chloride 0.4 g/l - blood substitutes and perfusion solutions

Sodium Chloride 0.9% Intravenous Infusion BP Malta - English - Medicines Authority

sodium chloride 0.9% intravenous infusion bp

baxter healthcare limited - sodium chloride - solution for infusion - sodium chloride 0.9 percent weight/volume - blood substitutes and perfusion solutions

Sodium Chloride Intravenous Infusion BP 0.9% w/v (viaflex container) Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride intravenous infusion bp 0.9% w/v (viaflex container)

baxter holding b.v. - sodium chloride - solution for infusion - 0.9 percent weight/volume - electrolyte solutions; sodium chloride

PLASMA-LYTE 148 (approx. pH 7.4) 1000mL injection bag AHB2544 Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 1000ml injection bag ahb2544

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

PLASMA-LYTE 148 (approx. pH 7.4) 500mL injection bag AHB2543 Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 500ml injection bag ahb2543

baxter healthcare pty ltd - sodium gluconate, quantity: 5.02 g/l; sodium acetate, quantity: 3.68 g/l; sodium chloride, quantity: 5.26 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; potassium chloride, quantity: 370 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

PAMIDRONATE DISODIUM OMEGA 9 MG/ML SOLUTION Canada - English - Health Canada

pamidronate disodium omega 9 mg/ml solution

omega laboratories limited - pamidronate disodium - solution - 9mg - pamidronate disodium 9mg - bone resorption inhibitors

VOLULYTE 6% Australia - English - Department of Health (Therapeutic Goods Administration)

volulyte 6%

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l; sodium chloride, quantity: 6.02 g/l; potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.